• Genmab’s operating profit fell to USD 986 million in the first nine months of 2026.
• Revenue rose 22% to USD 3.24 billion, helped by higher DARZALEX and Kesimpta royalties.
• Operating expenses climbed 35% to USD 2.02 billion.
• October brought positive Phase 3 topline results for epcoritamab, Rina-S and petosemtamab, supporting plans to engage regulators.
• Genmab maintained its 2026 financial guidance published August 6.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611051101PRIMZONEFULLFEED1001302074) on November 05, 2026, and is solely responsible for the information contained therein.